Claims
- 1. A method of ameliorating, inhibiting or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent.
- 2. The method according to claim 1 wherein said anti-pressor agent comprises one or more compounds selected independently from the group consisting of prostaglandin-E1, ACE inhibitors, AT1-receptor antagonists, α1-adrenergic receptor antagonists, β-adrenergic receptor antagonists, calcium channel blockers, direct acting vasodilators, NO donors, activators of guanylyl cyclase, activators of adenyl cyclase, and phosphodiesterase inhibitors.
- 3. The method of claim 2 wherein said anti-pressor agent is an activator of guanylyl cyclase or adenyl cyclase selected from the group consisting of YC-1 and forskolin.
- 4. The method of claim 2 wherein said anti-pressor agent is a direct acting vasodilator selected from the group consisting of hydralazine and NO donors.
- 5. The method of claim 4 wherein said NO donor is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidnomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, N-hydroxyl-L-arginine, S,S-dinitrosodthiol, and NO gas.
- 6. The method according to claim 2 wherein said anti-pressor agent is an angiotensin-II receptor antagonists selected from the group consisting of eprosartan, irbesartan, losartan, and valsartan, and mixtures thereof.
- 7. The method according to claim 2 wherein said anti-pressor agent is an ACE inhibitor selected from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, fosinopril, imidapril, lacidipine, libenzapril, lisinopril, moexipril, moveltipril, pentopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril, and mixtures thereof.
- 8. The method according to claim 2 wherein said anti-pressor agent is an α1-adrenergic antagonist selected from the group consisting of alfuzosin, apraclonidine, bunazosin, carvedilol, clonidine, dapiprazole, doxazosin, indoramin, labetolol, midrodrine, naphazoline, phenoxybenzamine, phentolamine, prazosin, tamsulosin, terazosin, trimazosin, and urapidil, and mixtures thereof.
- 9. The method according to claim 2 wherein said anti-pressor agent is a calcium channel blocker selected from the group consisting of bepridil, diltiazem, mibrefadil, nicardipine, nifedipine, nimopidine, and verapamil, and mixtures thereof.
- 10. The method according to claim 2 wherein said anti-pressor agent is a phosphodiesterase inhibitor selected from the group consisting of amrinone and sildenafil.
- 11. The method according to claim 2 wherein said anti-pressor agent is co-administered with a diuretic compound.
- 12. The method according to claim 2 wherein said anti-pressor agent is co-administered with prostaglandin-E1.
- 13. The method of claim 1 wherein said anti-pressor agent is administered to a normotensive patient.
- 14. The method of claim 1 wherein said anti-pressor agent is administered on a chronic basis at a dose ranging between one-twentieth to one-half the dose normally given to a hypertensive patient.
- 15. The method of claim 1 wherein said anti-pressor agent is administered for a period ranging between about three days to about twenty-one days at a dose ranging between one to three times the dose normally given to a hypertensive patient.
- 16. The method according to claim 14 wherein said anti-pressor agent is administered to a normotensive patient.
- 17. The method according to claim 15 wherein said anti-pressor agent is administered to a normotensive patient.
- 18. A method of remodeling the vascular bed which supplies blood to the genitalia, comprising administering to a patient in need thereof a therapeutically effective amount of an anti-pressor agent.
- 19. The method according to claim 18 wherein said anti-pressor agent compris es one or more compounds selected independently from the group consisting of prostaglandin-E1, ACE inhibitors, AT1-receptor antagonists, α1-adrenergic receptor antagonists, β-adrenergic receptor antagonists, calcium channel blockers, direct acting vasodilators, NO donors, activators of guanylyl cyclase, activators of adenyl cyclase, and phosphodiesterase inhibitors.
- 20. The method of claim 19 wherein said anti-pressor agent is an activator of guanylyl cyclase or adenyl cyclase selected from the group consisting of YC-1 and forskolin.
- 21. The method of claim 19 wherein said anti-pressor agent is a direct acting vasodilator selected from the group consisting of hydralazine and NO donors.
- 22. The method of claim 21 wherein said NO donor is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidnomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, N-hydroxyl-L-arginine, S,S-dinitrosodthiol, and NO gas.
- 23. The method according to claim 19 wherein said anti-pressor agent is an angiotensin-II receptor antagonists selected from the group consisting of eprosartan, irbesartan, losartan, and valsartan, and mixtures thereof.
- 24. The method according to claim 19 wherein said anti-pressor agent is and ACE inhibitor selected from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, fosinopril, imidapril, lacidipine, libenzapril, lisinopril, moexipril, moveltipril, pentopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril, and mixtures thereof.
- 25. The method according to claim 19 wherein said anti-pressor agent is an α1-adrenergic antagonist selected from the group consisting of alfuzosin, apraclonidine, bunazosin, carvedilol, clonidine, dapiprazole, doxazosin, indoramin, labetolol, midrodrine, naphazoline, phenoxybenzamine, phentolamine, prazosin, tamsulosin, terazosin, trimazosin, and urapidil, and mixtures thereof.
- 26. The method according to claim 19 wherein said anti-pressor agent is a calcium channel blocker selected from the group consisting of bepridil, diltiazem, mibrefadil, nicardipine, nifedipine, nimopidine, and verapamil, and mixtures thereof.
- 27. The method according to claim 19 wherein said anti-pressor agent is a phosphodiesterase inhibitor selected from the group consisting of amrinone and sildenafil.
- 28. The method according to claim 19 wherein said anti-pressor compound is co-administered with a diuretic agent.
- 29. The method according to claim 19 wherein said anti-pressor compound is co-administered with prostaglandin-E1.
- 30. The method of claim 18 wherein said anti-pressor agent is administered on a chronic basis at a dose ranging between one-twentieth to one-half the dose normally given to a hypertensive patient.
- 31. The method of claim 18 wherein said anti-pressor agent is administered for a period ranging between about three days to about twenty-one days at a dose ranging between one to three times the dose normally given to a hypertensive patient.
- 32. The method according to claim 30 wherein said anti-pressor agent is administered to a normotensive patient.
- 33. The method according to claim 31 wherein said anti-pressor agent is administered to a nornotensive patient.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to application Ser. No. 09/382,749 filed Aug. 25, 1999 which in turn claims priority to provisional application Ser. No. 60/098,178 filed Aug. 26, 1998.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60098178 |
Aug 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09382749 |
Aug 1999 |
US |
Child |
09902787 |
Jul 2001 |
US |